Top View
- 2021 Aetna Standard Plan
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- Endometriosis and Medical Therapy: from Progestogens to Progesterone Resistance to Gnrh Antagonists: a Review
- Luteinizing Hormone-Releasing Hormone Antagonists
- Elagolix | Memorial Sloan Kettering Cancer Center
- Endoshare: Personalizing Treatment of Endometriosis
- Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy Ayman Al‑Hendy, M.D., Ph.D., Andrea S
- How Effective Is Elagolix Treatment in Women with Fibroids and HMB?
- M12-817 Clinical Study Report R&D/17/0779
- Efficacy of Elagolix in the Treatment of Endometriosis
- Study Protocol and Statistical Analysis Plan
- Gonadotropin-Releasing Hormone Antagonists - Orilissa™ (Elagolix Tablets)
- 214846Orig1s000
- Oriahnn (Elagolix/Estradiol/Norethindrone
- Standard Commercial Drug Formulary Prior Authorization Guidelines
- Oral Gonadotropin-Releasing Hormone Antagonists NOTICE
- Elagolix, Estradiol, and Norethindrone Acetate) Effective 11/01/20
- M12-821 Clinical Study Report R&D/16/0647
- Elagolix: a New Treatment for Pelvic Pain Caused by Endometriosis
- Abbvie's Orilissa, Myovant's Relugolix Both Expected to Face Similar Payer
- Obseva Investor Deck JPM 2020
- WO 2010/032200 Al
- Gonadotropin-Releasing Hormone Antagonists – Myfembree® (Relugolix, Estradiol, and Norethindrone Acetate Tablets)
- Elagolix for Treating Endometriosis
- Endometriosis
- New Drug Evaluation: Elagolix Tablet, Oral
- Gnrh Modulators TCO 02.2019
- Your Patient Questions Her Ovarian Reserve 6 Answers to Common Questions Help Guide Your Clinical Approach
- Comparative Clinical Effectiveness of Elagolix for Endometriosis : Research Protocol Background, Objectives, and Research Questions
- Ryeqo, INN: Relugolix / Estradiol / Norethisterone Acetate